Literature DB >> 18317226

Grading of ovarian cancer: a histotype-specific approach.

Anais Malpica1.   

Abstract

Over the last decade, our understanding of ovarian cancer has evolved; it is no longer considered a single entity, but instead a heterogeneous group of tumors. Accordingly, a histotype-specific grading system seems to be more appropriate than a universal grading system to reflect the diversity of this disease. In this article, this histotype-specific approach to the grading of ovarian carcinoma is discussed.

Entities:  

Mesh：

Year:  2008        PMID： 18317226     DOI： 10.1097/PGP.0b013e31816085e0

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN： 0277-1691            Impact factor:   2.762


  15 in total

1.  Mucosal carcinoma of the fallopian tube coexists with ovarian cancer of serous subtype only: a study of Japanese cases.

Authors:  Daichi Maeda; Satoshi Ota; Yutaka Takazawa; Kenichi Ohashi; Masaya Mori; Tetsuo Imamura; Shunsuke Nakagawa; Tetsu Yano; Yuji Taketani; Masashi Fukayama
Journal:  Virchows Arch       Date:  2010-09-25       Impact factor: 4.064

Review 2.  [Histological grading of epithelial ovarian cancer. Review and recommendation].

Authors:  S Hauptmann; A du Bois; I Meinhold-Herlein; J Pfisterer; S Avril
Journal:  Pathologe       Date:  2014-09       Impact factor: 1.011

3.  Clinical and prognostic value of the presence of irregular giant nuclear cells in pT1 ovarian clear cell carcinoma.

Authors:  Naoki Matsumoto; Takashi Umezawa; Toru Sasaki; Kuninobu Nakajima; Yukiko Kanetsuna; Hiroshi Sasaki
Journal:  Pathol Oncol Res       Date:  2011-01-28       Impact factor: 3.201

4.  Histological grading in a large series of advanced stage ovarian carcinomas by three widely used grading systems: consistent lack of prognostic significance. A translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol).

Authors:  Stefan Kommoss; Dietmar Schmidt; Friedrich Kommoss; Juergen Hedderich; Philipp Harter; Jacobus Pfisterer; Andreas du Bois
Journal:  Virchows Arch       Date:  2009-01-27       Impact factor: 4.064

5.  Expression of MAGE-C1/CT7 and selected cancer/testis antigens in ovarian borderline tumours and primary and recurrent ovarian carcinomas.

Authors:  Anne-Katrin Zimmermann; Jochen Imig; Agnes Klar; Christoph Renner; Dimitri Korol; Daniel Fink; Sylvia Stadlmann; Gad Singer; Alexander Knuth; Holger Moch; Rosmarie Caduff
Journal:  Virchows Arch       Date:  2013-03-26       Impact factor: 4.064

6.  Agreement for tumor grade of ovarian carcinoma: analysis of archival tissues from the surveillance, epidemiology, and end results residual tissue repository.

Authors:  Rayna K Matsuno; Mark E Sherman; Kala Visvanathan; Marc T Goodman; Brenda Y Hernandez; Charles F Lynch; Olga B Ioffe; David Horio; Charles Platz; Sean F Altekruse; Ruth M Pfeiffer; William F Anderson
Journal:  Cancer Causes Control       Date:  2013-02-03       Impact factor: 2.506

Review 7.  Ovarian cancer: genomic analysis.

Authors:  W Wei; D Dizon; V Vathipadiekal; M J Birrer
Journal:  Ann Oncol       Date:  2013-12       Impact factor: 32.976

Review 8.  [Grading of gynecological tumors : Current aspects].

Authors:  L-C Horn; D Mayr; C E Brambs; J Einenkel; I Sändig; K Schierle
Journal:  Pathologe       Date:  2016-07       Impact factor: 1.011

9.  A prognostic system for epithelial ovarian carcinomas using machine learning.

Authors:  Philip M Grimley; Zhenqiu Liu; Kathleen M Darcy; Matthew T Hueman; Huan Wang; Li Sheng; Donald E Henson; Dechang Chen
Journal:  Acta Obstet Gynecol Scand       Date:  2021-03-18       Impact factor: 4.544

10.  Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors.

Authors:  Véronique Ouellet; Tak Hay Ling; Karine Normandin; Jason Madore; Christian Lussier; Véronique Barrès; Dimcho Bachvarov; Claudine Rancourt; Patricia N Tonin; Diane M Provencher; Anne-Marie Mes-Masson
Journal:  BMC Cancer       Date:  2008-11-26       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.